These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 22966129

  • 1. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I.
    J Infect Dis; 2012 Nov 15; 206(10):1542-8. PubMed ID: 22966129
    [Abstract] [Full Text] [Related]

  • 2. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H.
    J Infect Dis; 2008 Apr 01; 197(7):950-6. PubMed ID: 18419470
    [Abstract] [Full Text] [Related]

  • 3. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S, Esteghamati AR, Shiva F, Fallah F, Radmanesh R, Abdinia B, Shamshiri AR, Khairkhah M, Shekari Ebrahimabad H, Karimi A.
    Arch Iran Med; 2013 Jan 01; 16(1):38-41. PubMed ID: 23273235
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T, Baer M, Willems P.
    Pediatr Infect Dis J; 2007 Feb 01; 26(2):153-8. PubMed ID: 17259879
    [Abstract] [Full Text] [Related]

  • 5. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ, Li Q, Yan R, Zhou Y, Tang XW, Deng X, Xie SY, Chen ZP.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr 06; 51(4):336-340. PubMed ID: 28395468
    [Abstract] [Full Text] [Related]

  • 6. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
    Seagle EE, Bednarczyk RA, Hill T, Fiebelkorn AP, Hickman CJ, Icenogle JP, Belongia EA, McLean HQ.
    Vaccine; 2018 Feb 01; 36(6):818-826. PubMed ID: 29317117
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.
    Pediatr Infect Dis J; 2008 Aug 01; 27(8):724-30. PubMed ID: 18600190
    [Abstract] [Full Text] [Related]

  • 8. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K, Nicoara C, Germann D, Matter L.
    Schweiz Med Wochenschr; 1998 Apr 25; 128(17):649-57. PubMed ID: 9622837
    [Abstract] [Full Text] [Related]

  • 9. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S.
    Bone Marrow Transplant; 2004 Jun 25; 33(12):1187-90. PubMed ID: 15077129
    [Abstract] [Full Text] [Related]

  • 10. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE.
    J Infect Dis; 2004 May 01; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [Abstract] [Full Text] [Related]

  • 11. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M, Palmu AA, Syrjänen RK, Lahdenkari M, Ruokokoski E, Davidkin I, Vaarala O, Melin M.
    J Infect Dis; 2016 Jun 15; 213(12):2005-13. PubMed ID: 26908733
    [Abstract] [Full Text] [Related]

  • 12. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H.
    J Trop Pediatr; 2011 Oct 15; 57(5):347-51. PubMed ID: 21078605
    [Abstract] [Full Text] [Related]

  • 13. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL, Castaneda D, Arellano Quintanilla DM, Martínez D, Trumbo SP, Fernández de Castro J.
    Vaccine; 2017 May 25; 35(23):3116-3122. PubMed ID: 28457672
    [Abstract] [Full Text] [Related]

  • 14. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR, Camacho LA, Siqueira MM, Freire Mde S, Castro YP, Maia Mde L, Yamamura AM, Martins RM, Leal Mde L, Collaborative Group for the Study of Yellow Fever Vaccines.
    Vaccine; 2011 Aug 26; 29(37):6327-34. PubMed ID: 21640779
    [Abstract] [Full Text] [Related]

  • 15. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults.
    Kakoulidou M, Ingelman-Sundberg H, Johansson E, Cagigi A, Farouk SE, Nilsson A, Johansen K.
    Vaccine; 2013 Jan 11; 31(4):711-7. PubMed ID: 23174196
    [Abstract] [Full Text] [Related]

  • 16. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G.
    Pediatr Infect Dis J; 2005 Dec 11; 24(12):1083-8. PubMed ID: 16371870
    [Abstract] [Full Text] [Related]

  • 17. Mumps, measles and rubella vaccination in children with PFAPA syndrome.
    Kraszewska-Głomba B, Matkowska-Kocjan A, Miśkiewicz K, Szymańska-Toczek Z, Wójcik M, Banyś D, Szenborn L.
    Vaccine; 2016 Nov 21; 34(48):5903-5906. PubMed ID: 27997341
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group.
    Vaccine; 2018 Sep 11; 36(38):5781-5788. PubMed ID: 30104117
    [Abstract] [Full Text] [Related]

  • 19. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S, Feyssaguet M, Povey M, Di Paolo E.
    Vaccine; 2019 Aug 23; 37(36):5323-5331. PubMed ID: 31345639
    [Abstract] [Full Text] [Related]

  • 20. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
    King SM, Saunders EF, Petric M, Gold R.
    Bone Marrow Transplant; 1996 Apr 23; 17(4):633-6. PubMed ID: 8722367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.